Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 7/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.35 |
| ▸ | ITGAV | P06756 | 4/20 | 0.35 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.35 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20550882 | 1.00 | TRPV1 (0.39) | TRPV1AXLGRM5MEN1KMT2A | |
| SCHEMBL17769682 | 0.95 | TRPV1 (0.38) | TRPV1AXLGRM5MEN1KMT2A | |
| SCHEMBL17769686 | 0.95 | TRPV1 (0.38) | TRPV1AXLGRM5MEN1KMT2A | |
| SCHEMBL17769549 | 0.89 | AXL (0.34) | AXL | |
| SCHEMBL17769550 | 0.89 | AXL (0.34) | AXL | |
| SCHEMBL17777088 | 0.89 | TRPV1 (0.39) | TRPV1AXLMEN1KMT2A | |
| SCHEMBL19714570 | 0.89 | TRPV1 (0.39) | TRPV1AXLMEN1KMT2A | |
| SCHEMBL19714404 | 0.89 | TRPV1 (0.39) | TRPV1AXLMEN1KMT2A | |
| SCHEMBL19714221 | 0.86 | TRPV1 (0.37) | TRPV1AXLGRM5TRPM8 | |
| SCHEMBL19714137 | 0.86 | TRPV1 (0.37) | TRPV1AXLGRM5TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180319810-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2018-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319810-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | TRPV1 3814/4885AXL 542/4885GRM5 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.